World Journal of Surgery

, Volume 32, Issue 9, pp 2127–2128 | Cite as

Continuing Debate on D2 Lymphadenectomy for Gastric Cancer

  • Dimosthenis Ziogas
  • George Baltogiannis
  • Michael Fatouros
Article

References

  1. 1.
    Sano T (2007) Tailoring treatments for curable gastric cancer. Br J Surg 94(3):263–264PubMedCrossRefGoogle Scholar
  2. 2.
    Siewert JR, Bottcher K, Stein HJ et al (1998) Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg 228(4):449–461PubMedCrossRefGoogle Scholar
  3. 3.
    Roukos DH, Kappas AM (2002) Targeting the optimal extent of lymph node dissection for gastric cancer. J Surg Oncol 81:59–62PubMedCrossRefGoogle Scholar
  4. 4.
    Kappas AM, Fatouros M, Roukos DH (2004) Is it time to change surgical strategy for gastric cancer in the United States? Ann Surg Oncol 11:727–730PubMedCrossRefGoogle Scholar
  5. 5.
    Roukos DH (2000) Extended (D2) lymph node dissection for gastric cancer: do patients benefit? Ann Surg Oncol 7:253–255PubMedCrossRefGoogle Scholar
  6. 6.
    Roukos DH, Kappas AM (2005) Perspectives in the treatment of gastric cancer. Nat Clin Pract Oncol 2:98–107PubMedCrossRefGoogle Scholar
  7. 7.
    Roukos DH (1999) Current advances and changes in treatment strategy may improve survival and quality of life in patients with potentially curable gastric cancer. Ann Surg Oncol 6:46–56PubMedCrossRefGoogle Scholar
  8. 8.
    Wu CW, Hsiung SA, Lo SS et al (2006) Nodal dissection for patients with gastric cancer: a randomized trial. Lancet Oncol 7:309–315PubMedCrossRefGoogle Scholar
  9. 9.
    Roukos DH (1998) Extended lymphadenectomy in gastric cancer: when, for whom and why. Ann R Coll Surg Engl 80(1):16–24PubMedGoogle Scholar
  10. 10.
    Roukos DH, Hottenrott C, Encke A et al (1994) Primary gastric lymphomas: a clinicopathologic study with literature review. Surg Oncol 3(2):115–125PubMedCrossRefGoogle Scholar
  11. 11.
    Roukos DH (2004) Early-stage gastric cancer: a highly treatable disease. Ann Surg Oncol 11:127–129PubMedCrossRefGoogle Scholar
  12. 12.
    Park JM, Kim JH, Park SS et al (2008) Prognostic factors and availability of D2 lymph node dissection for the patients with stage II gastric cancer: comparative analysis of subgroups in stage II. World J Surg 32:1037–1044PubMedCrossRefGoogle Scholar
  13. 13.
    Liakakos T, Roukos DH (2008) More controversy than ever—challenges and promises towards personalized treatment of gastric cancer. Ann Surg Oncol 15(4):956–960PubMedCrossRefGoogle Scholar
  14. 14.
    Sakuramoto S, Sasako M, Yamaguchi T et al (2007) Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357:1810–1820PubMedCrossRefGoogle Scholar
  15. 15.
    Cunningham D, Allum WH, Stenning SP et al (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355:11–20PubMedCrossRefGoogle Scholar
  16. 16.
    Roukos DH (2002) Adjuvant chemoradiotherapy in gastric cancer: wave goodbye to extensive surgery? Ann Surg Oncol 9:220–221PubMedCrossRefGoogle Scholar
  17. 17.
    Macdonald JS, Smalley SR, Benedetti J et al (2001) Chemoradiotherapy after surgery compared with surgery alone for adenocarcinomas of the stomach or gastroesophageal junction. N Engl J Med 345:725–730PubMedCrossRefGoogle Scholar
  18. 18.
    Briasoulis E, Fatouros M, Roukos DH (2007) Level I evidence in support of perioperative chemotherapy for operable gastric cancer: sufficient for wide clinical use? Ann Surg Oncol 14:2691–2695PubMedCrossRefGoogle Scholar
  19. 19.
    Roukos DH, Lorenz M, Encke A (1998) Evidence of survival benefit of extended (D2) lymphadenectomy in Western patients with gastric cancer based on a new concept: a prospective long-term follow-up study. Surgery 123(5):573–578PubMedCrossRefGoogle Scholar
  20. 20.
    Briasoulis E, Liakakos T, Dova L et al (2006) Selecting a specific pre- or postoperative adjuvant therapy for individual patients with operable gastric cancer. Expert Rev Anticancer Ther 6:931–939PubMedCrossRefGoogle Scholar
  21. 21.
    Roukos DH, Murray S, Briasoulis E (2007) Molecular genetic tools shape a roadmap towards a more accurate prognostic prediction and personalized management of cancer. Cancer Biol Ther 6(3):308–312PubMedCrossRefGoogle Scholar
  22. 22.
    Norton JA, Ham CM, Van Dam J et al (2007) CDH1 truncating mutations in the E-cadherin gene: an indication for total gastrectomy to treat hereditary diffuse gastric cancer. Ann Surg 245(6):873–879PubMedCrossRefGoogle Scholar
  23. 23.
    Roukos DH, Kappas AM, Tsianos E (2002) Role of surgery in the prophylaxis of hereditary cancer syndromes. Ann Surg Oncol 9(7):607–609PubMedGoogle Scholar
  24. 24.
    Roukos DH, Briasoulis E (2007) Individualized preventive and therapeutic management of hereditary breast ovarian cancer. Nat Clin Pract Oncol 4(10):578–590PubMedCrossRefGoogle Scholar
  25. 25.
    Roukos DH (2008) Linking contralateral breast cancer with genetics. Radiother Oncol 86:139–141PubMedCrossRefGoogle Scholar
  26. 26.
    Fatouros M, Baltoyiannis G, Roukos DH (2008) The predominant role of surgery in the prevention and new trends in the surgical treatment of women with BRCA1/2 mutations. Ann Surg Oncol 15:21–33PubMedCrossRefGoogle Scholar
  27. 27.
    Roukos DH (2007) Prognosis of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 357(15):1555–1556; author reply 1556PubMedCrossRefGoogle Scholar
  28. 28.
    Roukos DH, Agnanti NJ, Paraskevaidis E et al (2002) Approaching the dilemma between prophylactic bilateral mastectomy or oophorectomy for breast and ovarian cancer prevention in carriers of BRCA1 or BRCA2 mutations. Ann Surg Oncol 9(10):941–943PubMedGoogle Scholar
  29. 29.
    Agnantis NJ, Paraskevaidis E, Roukos D (2004) Preventing breast, ovarian cancer in BRCA carriers: rational of prophylactic surgery and promises of surveillance. Ann Surg Oncol 11(12):1030–1034PubMedCrossRefGoogle Scholar
  30. 30.
    Roukos DH, Kappas AM, Agnantis NJ (2003) Perspectives and risks of breast-conservation therapy for breast cancer. Ann Surg Oncol 10:718–721PubMedCrossRefGoogle Scholar
  31. 31.
    Fatouros M, Roukos DH, Arampatzis I et al (2005) Factors increasing local recurrence in breast-conserving surgery. Expert Rev Anticancer Ther 5(4):737–745PubMedCrossRefGoogle Scholar
  32. 32.
    Roukos DH (2008) HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 358:197; author reply 198PubMedCrossRefGoogle Scholar
  33. 33.
    Roukos DH (2008) Breast-cancer stromal cells with TP53 mutations and nodal metastases. N Engl J Med 358:1636PubMedCrossRefGoogle Scholar
  34. 34.
    Roukos D (2008) Innovative genomic-based model for personalized treatment of gastric cancer: integrating current standards and new technologies. Expert Rev Mol Diagn 8(1):29–39PubMedCrossRefGoogle Scholar

Copyright information

© Société Internationale de Chirurgie 2008

Authors and Affiliations

  • Dimosthenis Ziogas
    • 1
  • George Baltogiannis
    • 1
  • Michael Fatouros
    • 1
  1. 1.Department of SurgeryUniversity of Ioannina, School of MedicineIoanninaGreece

Personalised recommendations